



Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 20 October 2021

Jobkeeper s323DB Notice

Sydney 20 October 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) provides the attached notice as required under subsection 323DB(1) of the Corporations Act 2001, being the Jobkeeper payments disclosure by a listed entity.

-ENDS-

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au



Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Jobkeeper Payments Notification

*A notice for release to the market under subsection 323DB(1) of the Corporations Act 2001-
jobkeeper payments disclosure by listed entity.*

Date of this notice

10/20/2021

Listed entity details

Australian Business Number (ABN)

50608966123

ASX/NSX/SSX issuer code

ASX:NOX

Name of the listed entity

NOXOPHARM LIMITED

Jobkeeper payments

This notice relates to the financial years ended 06/30/2020 (FY 1) and 06/30/2021 (FY 2).

The number of individuals for whom the listed entity or a subsidiary of the listed entity received a jobkeeper payment for a jobkeeper fortnight that ended in the financial year (within the meaning of the Coronavirus Economic Response Package (Payments and Benefits) Rules 2020).

FY 1:0 FY 2:0

The sum of all jobkeeper payments the listed entity, and each subsidiary of the listed entity, received in a jobkeeper fortnight that ended in the financial year.

FY 1:\$0 FY 2:\$0

Has the listed entity or a subsidiary of the listed entity, made one or more voluntary payments (whether or not in the financial year) to the Commonwealth by way of a repayment of jobkeeper payments received by the listed entity or a subsidiary of the listed in the financial year?

NO

If the listed entity or a subsidiary of the listed entity has made such a voluntary payment or payments -the sum of those payments:

FY 1:\$0 FY 2:\$0